Correction of systemic inflammation, oxidative stress and antioxidant defense using rosuvastatin in patients with chronic obstructive pulmonary disease


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Chronic obstructive pulmonary disease (COPD) - is a disease with still increased mortality. This article presents the results of evaluation of the effectiveness of rosuvastatin in patients with COPD and assessment its effect on systemic inflammation, oxidative stress, antioxidant defense, and clinical course of COPD (the number of exacerbations, severity of symptoms, the severity of dyspnea, exercise tolerance).

全文:

受限制的访问

作者简介

Yelena Samorukova

A.I. Yevdokimov Moscow State University of medicine and dentistry

Email: wlrad@bk.ru
senior laboratory assistant at the Department of outpatient therapy

Tatiana Adasheva

A.I. Yevdokimov Moscow State University of medicine and dentistry

Email: adashtv@mail.ru
MD, professor, professor of the Department of outpatient therapy

Sergey Pavlov

A.I. Yevdokimov Moscow State University of medicine and dentistry

Email: paseva@list.ru
PhD, assistant of the Department of outpatient therapy

参考

  1. Авдеев С.Н. Хроническая обструктивная болезнь легких как системное заболевание. Пульмонология. 2007;2:114-7. [Avdeev S.N. Chronic obstructive pulmonary disease as a systemic disease. Pulmonology. 2007;2:114-7 (in Russ.])
  2. Задионченко В.С., Адашева Т.В., Ли В.В., Жердева Е.И., Малиничева Ю.В., Нестеренко О.И., Павлов С.В. Артериальная гипертензия и хроническая обструктивная болезнь легких - проблема выбора терапии. Лечащий врач. 2012;7:77-81. [Zadionchenko V.C., Adasheva T.V., Lee V.V., Zherdeva Ye.I., Malanicheva Yu.V., Nesterenko O.I., Pavlov S.V. Arterial hypertension and chronic obstructive pulmonary disease - the problem of choice of therapy. Lechashchy vrach. 2012;7:77-81 (in Russ.])
  3. Обрезан А.Г., Куколь Л.В. Хроническая обструктивная болезнь легких и коморбидные кардиоваскулярные заболевания у лиц пожилого и старческого возраста: проблемы диагностики лечения (обзор литературы). Вестник СПбГУ. Серия 11. Медицина. 2010;2:51-66. [Obrezan A.G., Kukol' L.V. Chronic obstructive pulmonary disease and comorbid cardiovascular diseases in elderly and senile age: issues in diagnosis of treatment (literature review). Vestnik of St. Petersburg University. Series 11. Medicine. 2010;2:51-6 (in Russ.])
  4. Barjaktarevic I.Z., Arredondo A.F., Cooper C.B. Positioning new pharmacotherapies for COPD. Int. J. Chron. Obstruct. Pulmol. Dis. 2015;10:1427-42.
  5. Barnes P.J., Celli B.R. Systemic manifestations and co-morbidities in COPD. Eur. Respir. J. 2009;33:1 165-85.
  6. Ishida W., Kajiwara T., Ishii M., Fujiwara F., Taneichi H., Takebe N., Takahashi K., Kaneko Y., Segawa I., Inoue H., Satoh J. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J. Exp. Med. 2007;212:265-73.
  7. Dobler C.C., Wong K.K. Association between statins and COPD: a systematic review. BMC Pulmon. Med. 2009. URL: http://www.biomedcentral.com/1471-2466/9732.
  8. Backer J.D., Vos W., Holsbeke C.V., Vinchurkar S., Claes R., Parizel P.M., De Backer W. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2013;8:569-79.
  9. Zhang J.Q., Zhang J.Q., Liu H., Zhao Z.H., Fang L.Z., Liu L., Fu W.P., Shu J.K., Feng J.G., Dai L.M. Effects of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:917-23.
  10. Losano R., Naghavi M., Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128.
  11. Decramer M., Vogelmeier C., Agusti A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2016). 2016; URL: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html.
  12. Han M.K. Pharmacotherapeutic approach to preventing acute exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2011;8(4):356-62.
  13. Mortensen E.M., Copeland L.A., Pugh M.J., Restrepo M.I., de Molina R.M., Nakashima B., Anzueto A. Impact of statins and ACE inhibitors on mortality after COPD exacerbation. Respir. Res. 2009;10:45.
  14. Cazzola M., Calzetta L., Page C. et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a metaanalysis. Eur. Respor. Rev. 2015;24(137):451-61.
  15. Frost F.J., Petersen H., Tollestrup K., Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006-12.
  16. Liao J.K. Clinical implications for statin pleiotropy. Curr. Opin. Lipidol. 2005;6(16):624-9.
  17. Liao J.K. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005;45:89-118.
  18. Loukides S., Bartziokas K., Vestbo J., Singh D. Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. Curr. Drug Targets. 2013;14(2):235-45.
  19. Santus P., Corsico A., Solidoro P., Braido F., Di Marco F., Scichilone N. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine. COPD. 2014;11(6):705-17.
  20. Prabhala P., Ammit A. Tristetraprolin and its role in regulation of airway inflammation. Mol. Pharmacol. 2015;87(4):629-38.
  21. Quist-Paulsen P. Statins and inflammation: an update. Curr. Opin. Cardiol. 2010;25(4):399-405.
  22. Manchini G.B., Etminan M., Zhang B., Levesque L.E., FitzGerald J.M., Brophy J.M. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2006;47(12):2554-60.
  23. Siafakas N.M. Perventing exacerbations of COPD-advice from Hippocrares. N. Engl. J. Med. 2011;365(8):753-4.
  24. Smith M.C., Wrobel J.R. Epidemiology and clinic impact of major comorbidities in patients with COPD. Int. J. Chon. Obstruct. Pulmon. Dis. 2014;9:871-88.
  25. Ingebrigtsen T.S., Marott J.L., Nordestgaard B.G., Lange P., Hallas J., Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33-40.
  26. Soyseth V., Brekke P.H., Smith P., Omland T. Statin use in associated with reduced mortality in COPD. Eur. Respir. J. 2007;29(2):279-83.
  27. Alexeeff S.E., Litonjua A.A., Sparrow D., Vokonas P.S., Schwartz J. Statin use reduces decline in lung function. Am. J. Respir. Crit. Care Med. 2007;176(8):742-7.
  28. Janda S., Park K., FitzGerald J.M., Etminan M., Swiston J. Statins in COPD: a systematic review. Chest. 2009;136(3):734-43.
  29. Blamond A.I., Batty G.N., DeBary V.A., Rashid A.O., Sheikh M., Khan M.A. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int. J. Clin. Pract. 2008;62(9):1373-8.
  30. Khurana V., Bejjanki H.R., Caldioto G., Owens M.W. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest. 2007;131(5):1282-8.
  31. Farwell W.R., Scranton R.E., Lawler E.V., Lew R.A., Brophy M.T., Fiore L.D., Gaziano J.M. The association between statins and cancer incidence in a veterans population. J. Natl. Cancer Inst. 2008;100(2):134-9.
  32. Keddissi J.I., Younis W.G., Chbeir E.A., Daher N.N., Dernaika T.A., Kinasewitz G.T. The use of statins and lung function in current and former smokers. Chest. 2007;132(6):1764-71.
  33. Tse H.N., Tseng C.Z. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmol. Dis. 2014;9:825-36.
  34. Young R., Hopkins R. Comorbidities in COPD. Eur. Respir. J. 2009;34(6):1497-98.
  35. Young R. Statins in lung disease. URL: http://gpcme.co.nz/pdf/YoungStatins.pdf
  36. Young R.P., Hopkins R.J., Eaton T.E. Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev.2009;18(114):222-32.
  37. Young R.P., Hopkins R.J. Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. Expert Rev. Respir. Med. 2013;7(5):533-44.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##